BofA Securities analyst Jason Zemansky maintains $Travere Therapeutic (TVTX.US)$ with a buy rating, and adjusts the target price from $18 to $20.
According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 23.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Following a discussion with a nephrology specialist regarding the outcomes of the PARASOL Scientific Workshop, there is observed excitement about utilizing proteinuria as a primary endpoint in clinical trials. Should regulatory bodies embrace this approach, it would bode well for therapies targeting conditions such as focal segmental glomerulosclerosis (FSGS). Anticipating a potential launch in the future, the likelihood of success for such treatments is being cautiously estimated.
Following the conclusion of the PARASOL workshop, there is increased confidence in Filspari's potential approval for focal segmental glomerulosclerosis, or FSGS. This has led to a raised probability of success estimate for Filspari FSGS to 75% from the previous 60%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Jason Zemansky維持$Travere Therapeutic (TVTX.US)$買入評級，並將目標價從18美元上調至20美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.0%，總平均回報率為23.1%。
此外，綜合報道，$Travere Therapeutic (TVTX.US)$近期主要分析師觀點如下：
在與腎臟病專家討論了PARASOL科學研討會的結果之後，人們對使用蛋白尿作爲臨床試驗的主要終點感到興奮。如果監管機構採用這種方法，那對於針對局竈性節段性腎小球硬化（FSGS）等疾病的療法來說是個好兆頭。預計未來可能會推出此類療法，因此正在謹慎估計此類療法成功的可能性。
PARASOL研討會結束後，人們對Filspari可能批准局竈性節段性腎小球硬化（FSGS）的信心增強。這導致Filspari FSGS的成功概率從之前的60％提高到75％。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
